

## SINA TRAVEL CLINIC – VACCINE LIST

Property of SINA PHARMACY & MEDICAL CLINIC

VACCINE	STANDARD DOSE	BOOSTER INFORMATION	INDICATION	PUBLIC FUNDING CRITERIA	CONTRAINDICATIONS	SIDE EFFECTS
<b>Adacel</b>	1 dose	Tetanus and diphtheria toxoid boosters are recommended every 10 years.	<a href="#">Tetanus, Diphtheria, Pertussis</a>	<p><i>Publicly funded for:</i> Adults with no history of immunizations. Adults born 1989 or later who missed grade 9 Tdap booster (1 dose) Adults who have received a primary series are recommended to receive a one-time booster of Tdap (for pertussis protection – not provided free)</p>	Encephalopathy (e.g., coma, decreased level of consciousness, prolonged seizures) within 7 days of a previous dose of a pertussis-containing vaccine	General injection site side effects (pain, swelling, redness), fatigue, headache
<b>Bexsero</b>	Children 2 – 10 years old: 2 doses (months 0, 2) Adults 11-17 years old: 2 doses (months 0, 1)	The need for a subsequent dose after this vaccination schedule has not been established.	<a href="#">Meningococcal Meningitis B</a>	<p><i>Publicly funded for adults based on additional criteria:</i> Provided free to contacts of a case up to 55 years of age Recommended but not provided free: high risk individuals up to 55 years of age (asplenia, acquired or congenital immune deficiencies); researchers, military personnel, and travellers.</p>	Hypersensitive to this vaccine or to any ingredient in the formulation	Pain, redness, and induration injection site
<b>Cervarix</b>	3 doses (months 0, 1, 6)	The necessity for a booster has not been established.	<a href="#">HPV</a>	<p><i>Publicly funded for:</i> Females born in 1994 or later who were not immunized in the school-based program, or did not <i>complete</i> their vaccine series</p> <p><i>Publicly funded for adults based on additional criteria:</i> Provided free to HIV positive individuals 9 to 26 years of age (inclusive), males 9-26 years who are men who have sex with men or are questioning their sexual orientation, street involved, male 9-18 years (inclusive) in care of Ministry of Children and Family Development, males in youth custody and transgender individuals 9-26 years.</p>	Hypersensitive to this vaccine or to any ingredient in the formulation	General injection site side effects (pain, swelling, redness), fatigue, headache
<b>Dukoral</b>	2 doses (weeks 0, 1) 1 booster dose	If the patient received the last dose between 3 months and 5 years before, one booster dose will be sufficient to renew the protection. If the patient received the last dose more than 5 years before, a complete primary immunization (2 doses) is recommended to renew the protection.	Travellers' Diarrhea, <a href="#">Cholera</a>	<p><i>Require purchase:</i> Recommended for adults travelling to high risk areas</p>	<p><i>Hypersensitive to this vaccine or to any ingredient in the formulation.</i> <i>Should be deferred in the presence of acute gastrointestinal illness or acute febrile illness to avoid superimposing adverse effects from the vaccine on the underlying illness</i></p>	Diarrhea, abdominal cramp, flatulence
<b>Engerix B</b>	3 doses (months 0, 1, 6)	Protection has been shown to last for at least 15 years.	<a href="#">Hepatitis B</a>	<p><i>Publicly funded for:</i> All adults born on or after January 1, 1980.</p> <p><i>Publicly funded for adults based on additional criteria:</i> Post exposure and pre exposure for all students of health care professions; immunizing pharmacists; chronic liver and kidney disease, kidney transplant; HIV; HSCT recipients; individuals receiving repeated blood transfusions and haemophilia; MSM; multiple sex partners; history of recent STI; Illicit drug users and sexual partners; inmates; staff and residents of homes for the developmentally disabled; teachers and classroom contacts of a known hepatitis B carrier who is developmentally challenged and poses a risk; staff in daycare setting with Hep B infected child; household contacts of internationally adopted children.</p>	Hypersensitive to this vaccine or to any ingredient in the formulation	Irritability, headache, pain and redness at injection site, gastrointestinal symptoms (nausea, vomiting).

VACCINE	STANDARD DOSE	BOOSTER INFORMATION	INDICATION	PUBLIC FUNDING CRITERIA	CONTRAINDICATIONS	SIDE EFFECTS
				Recommended but not provided free for travellers.		
<b>Gardasil</b>	3 doses (months 0, 2, 6) 3 doses (months 0, 1, and 3 month after 2nd dose).	Additional (booster) doses are not recommended	<a href="#">HPV</a>	<i>Publicly funded for:</i> All adult females born 1994 or later to 26 years of age inclusive. <i>Require purchase:</i> Females born 1993 and earlier including older females at ongoing risk	Hypersensitive to this vaccine or to any ingredient in the formulation	General injection site side effects (pain, swelling, redness), fatigue, headache
<b>Havrix</b>	2 doses (months 0, 1-6)	Long-term persistence of serum antibodies to hepatitis A virus after vaccination with Havrix is under evaluation. Nevertheless, data available after 5 years show persistence of antibodies which is consistent with a projected 20 years persistence (based on mathematical calculations).	<a href="#">Hepatitis A</a>	<i>Publicly funded for adults based on additional criteria:</i> Anti-HAV IgG negative: individuals with haemophilia A or B, chronic liver disease, HIV, HSCT recipients, individuals receiving repeated blood transfusions, MSM, illicit drug users, inmates; close contacts of a hepatitis A case. Recommended but not provided free for food handlers and travellers.	Hypersensitive to this vaccine or to any ingredient in the formulation	Irritability, headache, pain and redness at injection site
<b>Havrix Jr</b>	2 doses (months 0, 1-6)	See above for how long immunity lasts.	<a href="#">Hepatitis A</a>		Hypersensitive to this vaccine or to any ingredient in the formulation	Irritability, headache, pain and redness at injection site
<b>Imovax Polio</b>	1 dose	Adults and adolescents who are at greater risk of exposure to poliovirus than the general population (see above) may be given a single dose of IPV if more than 10 years have elapsed since the last dose of their <b>complete</b> IPV and/or OPV vaccination series.	<a href="#">Polio</a>	<i>Publicly funded for adults based on additional criteria</i> Persons at high risk of exposure to wild polioviruses: travellers, health care and refugee camp workers, lab workers, military personnel, transplant candidate/recipient. Only give booster to HCW and lab workers who may be exposed to feces.	Should be deferred in the presence of any acute illness, including febrile illness, to avoid superimposing adverse effects from the vaccine on the underlying illness	Pain, redness, and induration at injection site
<b>Imovax Rabies</b>	3 doses (days 0, 7, 21-28)	Immunity lasts for at least 2 years. Persons with continuing high risk of exposure such as veterinarians, should have their serum tested for rabies antibodies every 2 years; others working with live rabies virus in laboratories or vaccine-production facilities and who are at risk of inapparent exposure should be tested every 6 months.	<a href="#">Rabies</a>	<i>Publicly funded for adults based on additional criteria:</i> BC students attending a vet college or animal health tech training centre. Recommended but not provided free to low-high risk workers, hunters, and some travellers.	Hypersensitive to this vaccine or to any ingredient in the formulation	Pain and redness at injection site, muscle ache, dizziness, gastrointestinal symptoms (abdominal pain, vomiting, diarrhea)
<b>Influenza vaccine</b>	1 dose	Annual revaccination with the current vaccine is recommended because immunity declines during the year after vaccination, and because circulating strains of influenza virus change from year to year.	<a href="#">Influenza</a>	<i>Publicly funded for adults based on additional criteria:</i> All adults > 65 years of age; adults < 65 who are at high risk of influenza complications; pregnant women in all stages of pregnancy; adults who are in close contact with those at high risk of influenza complications; essential community service providers. Recommended but not provided free for all others.	Hypersensitivity to egg proteins or after previous administration of any influenza vaccine produced in eggs or to any component of the vaccine.	Pain and redness at injection site, fatigue, headache, and muscle ache
<b>Ixiaro</b>	2 doses (days 0, 28)	A booster dose (third dose) should be given within the second year (i.e. 12-24 months) after the recommended primary immunization, prior to potential re-exposure to JEV. Persons at continuous risk for acquiring Japanese encephalitis( laboratory personnel or persons residing in endemic areas) should receive a booster dose at month 12 after primary immunization.	<a href="#">Japanese Encephalitis</a>	<i>Require purchase:</i> Recommended for adults travelling to high risk areas	Hypersensitive to this vaccine or to any ingredient in the formulation	Headache, fatigue, flu-like symptoms, muscle pain, nausea

VACCINE	STANDARD DOSE	BOOSTER INFORMATION	INDICATION	PUBLIC FUNDING CRITERIA	CONTRAINDICATIONS	SIDE EFFECTS												
<b>Menactra</b>	1 dose	The need for, or timing of, the administration of a booster has not yet been determined.	<a href="#">Meningococcal Meningitis ACYW135</a>	<i>Publicly funded for adults based on additional criteria:</i> Medically high risk individuals: functional or anatomic asplenia, transplant recipient**, congenital immunodeficiency; close contacts of a case (A,C, Y, or W-135). Recommended but not provided free: Some travellers, military recruits, research, industrial and clinical laboratory personnel who are at risk.	Hypersensitive to this vaccine or to any ingredient in the formulation	Pain, redness, swelling and induration at injection site, headache, and fatigue												
<b>Menjugate</b>	1 dose	The need for booster doses in subjects primed with a single dose (i.e. aged 12 months or more when first immunized) has not yet been established.	<a href="#">Meningococcal Meningitis C</a>	<i>Publicly funded for all adults:</i> Adults up to 24 years of age inclusive for those who have not received a dose at 10 years of age or older.	Hypersensitive to this vaccine or to any ingredient in the formulation	Pain, redness, induration at injection site, fever												
<b>M-M-R II</b>	1 dose	A second dose of measles-containing vaccine should be deferred for HIV-infected persons with moderate or advanced immunodeficiency. If the prevention of sporadic measles outbreaks is the sole objective, revaccination with a measles-containing vaccine should be considered. If concern also exists about immune status regarding mumps or rubella, revaccination with appropriate mumps- or rubella-containing vaccine should be considered.	<a href="#">Measles, Mumps, Rubella</a>	<i>Publicly funded for all adults:</i> <table border="1"> <thead> <tr> <th></th> <th>HCW</th> <th>Public</th> </tr> </thead> <tbody> <tr> <td>&lt;1957</td> <td>1</td> <td>0</td> </tr> <tr> <td>1957-1969</td> <td>2</td> <td>1</td> </tr> <tr> <td>1970+</td> <td>2</td> <td>2</td> </tr> </tbody> </table> Adults born prior to 1970 (1957 for HCW) are generally assumed to have acquired immunity to measles or mumps from natural infection. However, adults who are considered susceptible (no vaccine or disease) should be offered a series.		HCW	Public	<1957	1	0	1957-1969	2	1	1970+	2	2	Hypersensitive to this vaccine or to any ingredient in the formulation, including gelatin. Pregnant individuals Active, untreated tuberculosis Anaphylactic or anaphylactoid reactions to neomycin Patients receiving immunosuppressive therapy with ACTH, corticosteroids, irradiation, alkylating agents or antimetabolites Individuals with blood dyscrasias, leukemia, lymphomas of any type, or other malignant neoplasms affecting the bone marrow or lymphatic systems.	Diarrhea, fever, upper respiratory tract infections, irritability, cough,
	HCW	Public																
<1957	1	0																
1957-1969	2	1																
1970+	2	2																
<b>Pneumovax</b>	1 dose	If the person was older than 65 at the time of last vaccination, then no booster required; otherwise, booster is needed if more than 5 years has passed since last vaccine.	<a href="#">Pneumonia</a>	<i>Publicly funded for adults based on additional criteria</i> All Adults > 65 years of age; individuals with high risk medical conditions; residents of care facilities; homelessness or illicit drug use. Booster – Individuals with asplenia, sickle cell disease, immunosuppression or immunodeficiency, chronic kidney or liver disease, or chronic hepatitis C.	Hypersensitive to this vaccine or to any ingredient in the formulation	General injection site side effects (pain, swelling, redness), fatigue, headache												
<b>Shingrix</b>	2 dose (months 0, 2-6)	The need for booster doses following the primary vaccination schedule has not been established.	<a href="#">Shingles</a>	<i>Require purchase:</i> <i>Recommended for adults &gt;60 years of age; can also be used in individuals 50-59 years of age.</i>	Hypersensitive to this vaccine or to any ingredient in the formulation	General injection site side effects (pain, swelling, redness), fatigue, headache, muscle ache, nausea, vomiting, diarrhea.												
<b>Td Adsorbed</b>	1 dose	A booster is appropriate if the patient has not received a tetanus toxoid-containing preparation within the preceding 5 years.	<a href="#">Tetanus, Diphtheria</a>	<i>Publicly funded for all adults:</i> Adults with no history of immunizations. Adults born 1989 or later who missed grade 9 Tdap booster (1 dose) Adults who have received a primary series are recommended to receive a one-time booster of Tdap (for pertussis protection – not provided free)	Hypersensitive to this vaccine or to any ingredient in the formulation	General injection site side effects (pain, swelling, redness)												
<b>Twinrix</b>	3 doses (months 0, 1, 6)	Immunity is available up to 15 years after vaccination in adults and up to 10 years in infants, children and adolescents.	<a href="#">Hepatitis A &amp; B</a>	<i>Require purchase:</i> Recommended for adults travelling to high risk areas	Hypersensitive to this vaccine or to any ingredient in the formulation Anaphylactic or anaphylactoid reactions to neomycin	General injection site side effects (pain, swelling,												

VACCINE	STANDARD DOSE	BOOSTER INFORMATION	INDICATION	PUBLIC FUNDING CRITERIA	CONTRAINDICATIONS	SIDE EFFECTS
						redness), fatigue, headache
<b>Twinrix Jr</b>	3 doses (months 0, 1, 6)	See above for how long immunity lasts.	<a href="#">Hepatitis A &amp; B</a>		Hypersensitive to this vaccine or to any ingredient in the formulation Anaphylactic or anaphylactoid reactions to neomycin	General injection site side effects (pain, swelling, redness), fatigue, headache
<b>Typhim VI</b>	1 dose	Revaccination is recommended every three years under conditions of repeated or continuous exposure to <i>S. typhi</i> .	<a href="#">Typhoid Fever</a>	<i>Require purchase:</i> Recommended for adults travelling to high risk areas	Hypersensitive to this vaccine or to any ingredient in the formulation	General injection site side effects (pain, swelling, redness), fatigue, headache
<b>Varivax III</b>	Children 1 to 12 years old:1 dose Adults:2 doses (months 0, 1-2)	The duration of protection of VARIVAX III is unknown at present and the need for booster doses is not defined.	<a href="#">Chickenpox</a>	<i>Publicly funded for all adults:</i> Adults with no history of varicella/shingles on or after one year of age AND negative varicella IgG serology.	Hypersensitive to this vaccine or to any ingredient in the formulation, including gelatin <i>Pregnant individuals</i> <i>Active, untreated tuberculosis</i> <i>Anaphylactic or anaphylactoid reactions to neomycin</i> <i>Individuals with blood dyscrasias, leukemia, lymphomas of any type, or other malignant neoplasms affecting the bone marrow or lymphatic systems.</i> <i>Individuals receiving immunosuppressive therapy (including oral high-dose corticosteroids)</i> <i>Individuals with primary and acquired immunodeficiency state</i>	General injection site side effects (pain, swelling, redness), fever
<b>Vivotif (oral)</b>	4 doses (days 0, 2, 4, 7)	It is recommended that a booster dose consisting of 4 capsules taken on alternate days be given every 7 years under conditions of repeated or continued exposure to typhoid fever.	<a href="#">Typhoid Fever</a>	<i>Require purchase:</i> Recommended for adults travelling to high risk areas	Hypersensitive to this vaccine or to any ingredient in the formulation	General injection site side effects (pain, swelling, redness), fatigue, headache, nausea, vomiting, diarrhea
<b>Vivaxim</b>	1 dose	To provide long-term protection against infection caused by HAV, a booster injection of inactivated hepatitis A vaccine (such as AVAXIM) should be given 6 to 36 months later. Alternatively, VIVAXIM can be given as a booster vaccine at 36 months in those persons who require protection against typhoid fever.	<a href="#">Hepatitis A &amp; Typhoid fever</a>	<i>Require purchase:</i> Recommended for adults travelling to high risk areas	Hypersensitive to this vaccine or to any ingredient in the formulation	General injection site side effects (pain, swelling, redness), fatigue, headache, muscle ache
<b>YF-Vax</b>	1 dose	Booster is needed every 10 years.	<a href="#">Yellow Fever</a>	<i>Require purchase:</i> Recommended for adults travelling to high risk areas	Hypersensitive to this vaccine or to any ingredient in the formulation, including latex Hypersensitivity to the ingestion of eggs or chicken protein	Mild headache, muscle ache, low-grade fever
<b>Zostavax II</b>	1 dose	The duration of protection beyond 4 years after vaccination with Zostavax, the frozen formulation of zoster vaccine live, attenuated is unknown. The need for revaccination has not been defined.				